Novozymes A/S of Denmark has entered into a licensing and collaboration agreement with sanofi-aventis to develop a new antibiotic for severe infections caused by the bacteria, Staphylococcus and Streptococcus. Financial terms were not disclosed.
Novozymes A/S of Denmark has entered into a licensing and collaboration agreement with sanofi-aventis to develop a new antibiotic for severe infections caused by the bacteria, Staphylococcus and Streptococcus. Financial terms were not disclosed.